Abstract 52P
Background
The majority of colorectal cancers (CRCs), lung carcinomas (LCs) and melanomas contain hot-spot mutations in driver genes. This study evaluated the feasibility of disease monitoring using individual single-mutation tests for the analysis of circulating tumor DNA (ctDNA) in plasma.
Methods
The study included 49 patients with KRAS/BRAF-mutated CRC, EGFR-mutated LC, or BRAF-mutated melanoma, who received systemic treatment for metastatic disease. Blood samples were collected every 25-30 days; the number of time points varied from 2 to 12 for each patient with the individual follow-up ranging from 29 to 523 days (mean 208.7 ± 18.16). A total of 242 plasma samples were analyzed by droplet digital PCR to quantify ctDNA fragments carrying the corresponding driver mutation.
Results
In 25 patients (49%) no circulating mutant copies were detected in any of the serial samples; 24/25 (96%) of these ctDNA-negative subjects experienced either the reduction of tumor lumps or stable disease during the entire observation period. Twenty-four patients showed variations in the ctDNA status during the disease course. In 21/24 (88%) of these patients, the changes in the concentration of mutated ctDNA closely followed the dynamics of tumor volume as observed by computed tomography (CT). There were instances in which tumor progression was detected by liquid biopsy earlier than by imaging tools. One LC patient demonstrated an emergence of EGFR T790M mutation in the blood 126 days prior to tumor progression as registered by CT; in two other cases, the tumor growth was radiologically documented 23 and 34 days after the appearance of mutated ctDNA in plasma.
Conclusions
Serial ddPCR-based assessment of single driver mutations in ctDNA allows efficient monitoring of the efficacy of therapy in diverse categories of cancer patients. This work has been supported by the Russian Science Foundation grant #17-75-30027.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation grant #17-75-30027.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract
93P - A new platform for fast-track molecular stratification of endometrial carcinomas enabling timely treatment decisions in precision oncology
Presenter: Susanne Walz
Session: Cocktail & Poster Display session
Resources:
Abstract